
The Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty. The culture and environment at the Broad is designed to encourage creativity and to engage all participants, regardless of role or seniority, in the mission of the Institute. Within this setting, researchers are empowered — both intellectually and technically — to confront even the most difficult biomedical challenges. The Institute’s organization is unique among biomedical research institutions. It encompasses three types of organizational units: core member laboratories, programs and platforms. Scientists within these units work closely together — and with other collaborators around the world — to tackle critical problems in human biology and disease.
该公司进入各个市场的顺序 — 从最早到最新
Illumina推出TruPath基因组用于遗传病研究
因美纳推出TruPath Genome用于罕见病研究
注册以查看完整信号动态
Broad Institute Of MIT And Harvard 的国际扩张与竞争对手的对比情况
条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
Broad Institute Of MIT And Harvard你 | 0 | 0 | 0% | 0 | 18 |
IP Counsel
查看职位Cambridge, MA · 3周前
Senior Director, IT Optimization and Digital Experience
查看职位Cambridge, MA · 上个月
Research Scientist I - MDL
查看职位Cambridge, MA · 前天
没有进行中的营销活动
注册以跟踪该公司,并在发生变化时第一时间获得提醒。
丹娜-法伯癌症研究所的试验显示,个人化癌症疫苗对III/IV期透明细胞肾癌患者有效,九名参与者接受治疗后均未复发。
因美纳推出TruPath Genome,为罕见病研究提供全面基因组洞察,简化工作流程,提高难解基因组区域的准确性。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Broad Institute Of MIT And Harvard 的业务、市场和增长信号的快速解答。
